Endothelin Receptor Antagonist Ambrisentan, Sodium-Glucose Cotransporter 2 Inhibitor Henagliflozin, and Their Combination in IgA Nephropathy
Journal of the American Society of Nephrology · 2026-09 · 37 (9) · 2016-2026
DOI: 10.1681/asn.0000001097 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Society of Nephrology, online erschienen am 08.04.2026. Verfasst von Qinlan Chen und 19 weiteren Autor:innen. Beteiligte Einrichtung: Renal Division, Key Laboratory of Renal Disease, Peking University First Hospital, Peking University Institute of Nephrology, Ministry of Health of C…. Hauptthemen laut MEDLINE: Phenylpropionates, Sodium-Glucose Transporter 2 Inhibitors, Glomerulonephritis, IGA, Pyridazines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Capital's Funds for Health Improvement and Research, National Key Research and Development Program of China.
Abstract (Originalsprache)
Key Points Proteinuria responses to endothelin receptor antagonists and sodium-glucose cotransporter 2 inhibitors were not correlated. Ambrisentan-henagliflozin combination therapy reduced proteinuria similarly to ambrisentan monotherapy but exceeded henagliflozin alone. Combination therapy resulted in markedly less fluid retention and weight gain compared with endothelin receptor antagonist monotherapy.
Background
Sodium-glucose cotransporter 2 (SGLT2) inhibitors and endothelin receptor antagonists (ERAs) can reduce proteinuria and may slow kidney progression in IgA nephropathy. Their potential synergistic efficacy and safety are unclear.
Methods
This open-label randomized crossover trial enrolled adults with IgA nephropathy, eGFR >30 ml/min per 1.73 m 2 , and 24-hour urine protein-creatinine ratio (UPCR) ≥0.44 g/g or 24-hour urine protein ≥0.5 g, despite maximal renin-angiotensin system blockade. Treatments were given in random order (ambrisentan 5 mg/d, henagliflozin 10 mg/d, and combination), each for 4 weeks followed by a 4-week washout. Primary end point was correlation between treatments in 24-hour UPCR changes. Secondary end points included eGFR change. Safety end points included fluid retention (body weight change).
Results
Sixty-five patients were enrolled, with a mean baseline eGFR of 69 ml/min per 1.73 m 2 (SD=23) and a median 24-hour UPCR of 0.8 g/g (0.6–1.3). No correlation was found in 24-hour UPCR reduction between single-agent therapy and combination therapy (ambrisentan, r =0.13, P = 0.97; henagliflozin, r =0.04, P = 1.00). After treatment, the mean reduction in 24-hour UPCR was −44% with combination therapy (95% confidence interval [CI], −52 to −34), which was similar to ambrisentan alone (−48%; 95% CI, −56 to −39) but significantly superior to henagliflozin alone (−21%; 95% CI, −33 to −6). The mean reduction in eGFR from baseline was −4.7 ml/min per 1.73 m 2 (95% CI, −6.9 to −2.6) with combination therapy, which was significantly greater than with ambrisentan (−0.5 ml/min per 1.73 m 2 ; 95% CI, −2.8 to 1.9) but comparable with henagliflozin (−3.5 ml/min per 1.73 m 2 ; 95% CI, −5.8 to −1.2). Less fluid retention occurred with combination treatment versus ambrisentan alone.
Conclusions
Combining an ERA with an SGLT2 inhibitor further reduced proteinuria versus SGLT2 inhibitor alone, with less fluid retention than ERA alone. Clinical Trial registry name and registration number: Chinese Clinical Trial Registry (ChiCTR2400080435).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Renal Division, Key Laboratory of Renal Disease, Peking University First Hospital, Peking University Institute of Nephrology, Ministry of Health of China, Ministry of Education, Key Laboratory of Chronic Kidney Disease…
- Statistics Division, Peking University First Hospital, Beijing, China.
- The Second People's Hospital of Shanxi Province, Shanxi, China.
- Department of Nephrology, The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, Henan, China.
- Renal Division, Zhangzhou Municipal Hospital of Fujian Province, Fujian, China.
- Department of Nephrology, NHC Key Laboratory of Pulmonary Immunological Disease, Guizhou Provincial Key Laboratory of Pathogenesis and Prevention of Common Chronic Diseases Research, Guizhou Provincial People's Hospital…
ORCID-Profile: Qinlan Chen, Lijun Liu, Sufang Shi, Hongyu Yang, Yang Li, Ling Guo, Jinwei Wang, Qiong Zhang, Yuting Cai, Qian Wang, Hong Zhang
Förderung
- National Natural Science Foundation of China
- Capital's Funds for Health Improvement and Research
- National Key Research and Development Program of China
Zitieren
APA
Chen, Q., Chen, P., Liu, L., Shi, S., Zhou, X., Yang, H., Li, Y., Guo, L., Zhu, S., Wang, J., Bao, Y., Zhang, Q., Liu, M., Ning, X., Cai, Y., He, R., Liu, Y., Wang, Q., Lv, J., & Zhang, H. (2026). Endothelin Receptor Antagonist Ambrisentan, Sodium-Glucose Cotransporter 2 Inhibitor Henagliflozin, and Their Combination in IgA Nephropathy. Journal of the American Society of Nephrology, 37(9), 2016-2026. https://doi.org/10.1681/asn.0000001097
Vancouver
Chen Q, Chen P, Liu L, Shi S, Zhou X, Yang H, et al. Endothelin Receptor Antagonist Ambrisentan, Sodium-Glucose Cotransporter 2 Inhibitor Henagliflozin, and Their Combination in IgA Nephropathy. Journal of the American Society of Nephrology. 2026;37(9):2016-2026. doi:10.1681/asn.0000001097
BibTeX
@article{Chen2026,
author = {Chen, Qinlan and Chen, Pei and Liu, Lijun and Shi, Sufang and Zhou, Xujie and Yang, Hongyu and Li, Yang and Guo, Ling and Zhu, Sainan and Wang, Jinwei and Bao, Yunfei and Zhang, Qiong and Liu, Muqing and Ning, Xiaoyuan and Cai, Yuting and He, Rong and Liu, Yanjie and Wang, Qian and Lv, Jicheng and Zhang, Hong},
title = {Endothelin Receptor Antagonist Ambrisentan, Sodium-Glucose Cotransporter 2 Inhibitor Henagliflozin, and Their Combination in IgA Nephropathy},
journal = {Journal of the American Society of Nephrology},
year = {2026},
volume = {37},
number = {9},
pages = {2016--2026},
doi = {10.1681/asn.0000001097}
}
EUVIMED